Press Release Jul 21 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Norepinephrine Bitartrate Injection. This injection is used to restore blood pressure in adults experiencing acute hypotensive states. The drug will be manufactured at the company's facility in Jarod, India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jul 18 2022
- Press Release Jul 11 2022
- Press Release Jul 08 2022
- Press Release Jun 30 2022
- Press Release Jun 07 2022
Later from Zydus Lifesciences
- Press Release Jul 26 2022
- Press Release Aug 04 2022
- Press Release Aug 05 2022
- Press Release Aug 11 2022
- Press Release Aug 30 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences